AptarGroup (ATR) Pharma — Selling, research & development and administrative

Screener

Other segment segments

Beauty

$52.63M—

Closures

$24.95M—

Similar metrics at other companies

ITWSelling Administrative and Research and Development Expenses

$735M+6.1%

IEPPharma — Selling General And Administrative Expense

$14M0.0%

KALUSelling Administrative Research And Development And General Expenses

$35.7M+9.5%

IQVResearch & Development Solutions — Selling, general and administrative expenses

$248M+9.3%

VPGSensors — Selling General And Administrative Expense Excluding Research And Development

$5.49M+50.5%

VPGMeasurement Systems — Selling General And Administrative Expense Excluding Research And Development

$5M+7.9%

Other financials

Income statement

See full

Revenue$982.9M+10.8%

Gross profit$351.9M+4.6%

Operating income$107.5M-5.2%

Net income$72.7M-7.8%

EPS (diluted)$1.12-4.3%

Balance sheet

See full

Cash & equivalents$225.0M+78.8%

Total debt$1.4B+32.7%

Total equity$2.6B+3.6%

Total assets$5.1B+12.6%

Cash flow

See full

Operating cash flow$118.7M+43.5%

CapEx$65.4M+15.0%

Free cash flow$53.3M+106%

Valuation

See full

Market cap$8.69B-4.7%

Enterprise value$9.9B-2.2%

P/E22.5×-0.8×

P/S2.3×-0.3×

Profitability

See full

Gross margin36.7%-1.6pp

Operating margin12.8%-1.2pp

Net margin10%-0.4pp

FCF margin8.4%-2.1pp

Returns & leverage

See full

Return on equity15%-0.2pp

Debt / equity0.5×+0.1×

Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept atr:SellingResearchAndDevelopmentAndAdministrativeExpenses.

The source filing: AptarGroup’s 10-Q, filed May 1, 2026.

Filed: May 1, 2026, 11:22 AM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0000896622-26-000092

Three Months Ended March 31,	2026	2025
Beauty	271,488	224,048
Closures	131,883	122,391
Selling, Research & Development and Administrative:
Pharma	68,116	62,483
Beauty	52,630	46,412
Closures	24,945	23,012
Other Segment Items:
Pharma	(4,315)	(603)

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is AptarGroup's pharma — selling, research & development and administrative?: AptarGroup (ATR) reported pharma — selling, research & development and administrative of $68.12M in Q1 2026.
How has AptarGroup's pharma — selling, research & development and administrative changed year-over-year?: AptarGroup's pharma — selling, research & development and administrative increased by 9.0% year-over-year, from $62.48M to $68.12M.
What does pharma — selling, research & development and administrative mean?: Represents the operating expenses incurred for sales, marketing, administrative support, and research and development activities within the pharma segment. This reflects the investment in innovation and the overhead required to maintain market presence.